Fisher Funds Management LTD Sells 4,191 Shares of Amgen Inc. $AMGN

Fisher Funds Management LTD cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 14.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 25,650 shares of the medical research company’s stock after selling 4,191 shares during the quarter. Fisher Funds Management LTD’s holdings in Amgen were worth $9,025,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of AMGN. Robeco Institutional Asset Management B.V. raised its holdings in shares of Amgen by 10.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after purchasing an additional 43,884 shares during the last quarter. Curtis Advisory Group LLC acquired a new position in Amgen during the fourth quarter worth $1,669,000. Adell Harriman & Carpenter Inc. boosted its holdings in Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after purchasing an additional 1,609 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Amgen in the fourth quarter valued at $22,441,000. Finally, Sigma Planning Corp grew its position in Amgen by 24.0% in the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock valued at $5,889,000 after purchasing an additional 3,488 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Amgen stock opened at $337.60 on Monday. The firm has a market capitalization of $182.21 billion, a PE ratio of 23.49, a P/E/G ratio of 3.39 and a beta of 0.42. The company’s 50-day moving average is $340.71 and its 200-day moving average is $345.82. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the business posted $4.90 EPS. Amgen’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on AMGN shares. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Leerink Partners restated a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. Piper Sandler restated an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Royal Bank Of Canada lifted their target price on Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Finally, Guggenheim dropped their target price on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus target price of $354.42.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is owned by corporate insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.